Nebenwirkungen · Docetaxel Kabi
DOCETAXEL KABI 20 mg/1 ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 17–18
HOS-214548 · Präparat HOS-155350
17 MedDRA system Very common adverse Common adverse Uncommon adverse organ classes reactions reactions reactions Vascular disorders Hypotension (G3/4: 0.7%) Gastrointestinal Nausea (G3/4: 9.6%); Constipation disorders Vomiting (G3/4: 7.6%); Diarrhoea (G3/4: 6.4%); Stomatitis (G3/4: 2%) Skin and Alopecia; subcutaneous Nail disorders tissue disorders (severe: 0.7%); Skin reaction (G3/4: 0.2%) Musculoskeletal Myalgia (severe: 0.5%) and connective tissue disorders General disorders Asthenia (severe: 9.9%); Infusion site reaction; and administration Fluid retention Pain site conditions (severe: 0.7%); Fever (G3/4: 1.2%) Investigations G3/4 Blood bilirubin G3/4 AST increased increased (2.1%); G3/4 (0.5%); G3/4 Blood ALT increased (1.3%) alkaline phosphatase increased (0.3%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T15:44:00Z · SHA-256 4ec115d98d201d84de2340a9fdabdd8a6db17b0a20954d72cafab8a7e3eaf6e6 · Passage 533414b2746c9443553dd1f56b471643ca820e2116fb552f0c414c529af6abaa · Zeichen 15989–17306 im Abschnitt